BRST5:Adenoid cystic carcinoma - Revision history

Bailey.Glen at 17:44, 3 July 2025

2025-07-03T17:44:40Z

← Older revision		Revision as of 12:44, 3 July 2025
Line 28:		Line 28:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	~~\|MYB::NFIB fusion or MYBL1::NFIB fusion~~
	~~MYB or MYBL1 overexpression~~
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 22:04, 25 May 2025

2025-05-25T22:04:10Z

← Older revision		Revision as of 17:04, 25 May 2025
Line 88:		Line 88:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|6		\|6
Line 125:		Line 125:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 145:		Line 145:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|''MYB''		\|''MYB''

Bailey.Glen at 20:27, 25 May 2025

2025-05-25T20:27:19Z

← Older revision		Revision as of 15:27, 25 May 2025
Line 44:		Line 44:
	==Related Terminology==		==Related Terminology==


	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Carcinoma adenoides cysticum; adenocystic basal cell carcinoma; cylindromatous carcinoma
	\|}		\|}

Kgeiersbach: added gene fusion diagram, modified exonic breakpoints in table

2025-04-16T16:26:09Z

added gene fusion diagram, modified exonic breakpoints in table

← Older revision		Revision as of 11:26, 16 April 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Adenoid cystic carcinoma}}		{{DISPLAYTITLE:Adenoid cystic carcinoma}}

	[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]		[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

	~~{{Under Construction}}~~

	<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
	==Primary Author(s)*==		==Primary Author(s)*==
	Jun Liao, PhD, Columbia University Irving Medical Center, NY, USA		Jun Liao, PhD, Columbia University Irving Medical Center, NY, USA
Line 32:		Line 29:

	==WHO Essential and Desirable Genetic Diagnostic Criteria==		==WHO Essential and Desirable Genetic Diagnostic Criteria==


	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
Line 41:		Line 35:
	\|-		\|-
	\|WHO Desirable Criteria (Genetics)*		\|WHO Desirable Criteria (Genetics)*
	\|		\|MYB::NFIB fusion or MYBL1::NFIB fusion
			MYB or MYBL1 overexpression
	\|-		\|-
	\|Other Classification		\|Other Classification
Line 61:		Line 56:

	==Gene Rearrangements==		==Gene Rearrangements==
			[[File:MYB-NFIB fusion diagram.tif\|left\|frameless\|839x839px\|'''''MYB''::''NFIB'''''[GM1] . Gene fusion diagram showing the canonical breakpoints in exon 15 of ''MYB'' (NM_00130173) and exon 11 of ''NFIB'' (NM_001190737). Alternate fusion breakpoints in ''NFIB'' include exons 8, 9, or 12.]]
	<br />		<br />
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 72:		Line 68:
	\|''MYB''		\|''MYB''
	\|''MYB''::''NFIB''		\|''MYB''::''NFIB''
	\|Fusion transcripts ~~most commonly~~ join exon 8 or ~~exon~~ 14 of ''MYB'' with exon 9 of ''NFIB'' and result in overexpression of ''MYB''.<ref name=":2">{{Cite journal\|last=Persson\|first=Marta\|last2=Andrén\|first2=Ywonne\|last3=Mark\|first3=Joachim\|last4=Horlings\|first4=Hugo M.\|last5=Persson\|first5=Fredrik\|last6=Stenman\|first6=Göran\|date=2009-11-03\|title=Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck\|url=https://pubmed.ncbi.nlm.nih.gov/19841262\|journal=Proceedings of the National Academy of Sciences of the United States of America\|volume=106\|issue=44\|pages=18740–18744\|doi=10.1073/pnas.0909114106\|issn=1091-6490\|pmc=2773970\|pmid=19841262}}</ref><ref name=":1">{{Cite journal\|last=Brill\|first=Louis B.\|last2=Kanner\|first2=William A.\|last3=Fehr\|first3=André\|last4=Andrén\|first4=Ywonne\|last5=Moskaluk\|first5=Christopher A.\|last6=Löning\|first6=Thomas\|last7=Stenman\|first7=Göran\|last8=Frierson\|first8=Henry F.\|date=2011-09\|title=Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/21572406\|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc\|volume=24\|issue=9\|pages=1169–1176\|doi=10.1038/modpathol.2011.86\|issn=1530-0285\|pmid=21572406}}</ref><ref name=":3">{{Cite journal\|last=D'Alfonso\|first=Timothy M.\|last2=Mosquera\|first2=Juan Miguel\|last3=MacDonald\|first3=Theresa Y.\|last4=Padilla\|first4=Jessica\|last5=Liu\|first5=Yi-Fang\|last6=Rubin\|first6=Mark A.\|last7=Shin\|first7=Sandra J.\|date=2014-11\|title=MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features\|url=https://pubmed.ncbi.nlm.nih.gov/25217885\|journal=Human Pathology\|volume=45\|issue=11\|pages=2270–2280\|doi=10.1016/j.humpath.2014.07.013\|issn=1532-8392\|pmid=25217885}}</ref><ref name=":4">{{Cite journal\|last=Mitani\|first=Yoshitsugu\|last2=Liu\|first2=Bin\|last3=Rao\|first3=Pulivarthi H.\|last4=Borra\|first4=Vishnupriya J.\|last5=Zafereo\|first5=Mark\|last6=Weber\|first6=Randal S.\|last7=Kies\|first7=Merrill\|last8=Lozano\|first8=Guillermina\|last9=Futreal\|first9=P. Andrew\|date=2016-02-01\|title=Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations\|url=https://pubmed.ncbi.nlm.nih.gov/26631609\|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research\|volume=22\|issue=3\|pages=725–733\|doi=10.1158/1078-0432.CCR-15-2867-T\|issn=1557-3265\|pmc=4807116\|pmid=26631609}}</ref> Fusions translocate super-enhancers in the partner gene to ''MYB''.<ref>{{Cite journal\|last=Drier\|first=Yotam\|last2=Cotton\|first2=Matthew J.\|last3=Williamson\|first3=Kaylyn E.\|last4=Gillespie\|first4=Shawn M.\|last5=Ryan\|first5=Russell J. H.\|last6=Kluk\|first6=Michael J.\|last7=Carey\|first7=Christopher D.\|last8=Rodig\|first8=Scott J.\|last9=Sholl\|first9=Lynette M.\|date=2016-03\|title=An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma\|url=https://pubmed.ncbi.nlm.nih.gov/26829750\|journal=Nature Genetics\|volume=48\|issue=3\|pages=265–272\|doi=10.1038/ng.3502\|issn=1546-1718\|pmc=4767593\|pmid=26829750}}</ref> Fusion transcripts lack ''MYB'' exon 15 including the 3' UTR, which contains target sites for microRNAs that negatively regulate ''MYB.''<ref name=":2" />		\|Fusion transcripts join exon 8, 13, or 14 of ''MYB'' with exon 8, 9, 11, or 12 of ''NFIB'' and result in overexpression of ''MYB''.<ref name=":2">{{Cite journal\|last=Persson\|first=Marta\|last2=Andrén\|first2=Ywonne\|last3=Mark\|first3=Joachim\|last4=Horlings\|first4=Hugo M.\|last5=Persson\|first5=Fredrik\|last6=Stenman\|first6=Göran\|date=2009-11-03\|title=Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck\|url=https://pubmed.ncbi.nlm.nih.gov/19841262\|journal=Proceedings of the National Academy of Sciences of the United States of America\|volume=106\|issue=44\|pages=18740–18744\|doi=10.1073/pnas.0909114106\|issn=1091-6490\|pmc=2773970\|pmid=19841262}}</ref><ref name=":1">{{Cite journal\|last=Brill\|first=Louis B.\|last2=Kanner\|first2=William A.\|last3=Fehr\|first3=André\|last4=Andrén\|first4=Ywonne\|last5=Moskaluk\|first5=Christopher A.\|last6=Löning\|first6=Thomas\|last7=Stenman\|first7=Göran\|last8=Frierson\|first8=Henry F.\|date=2011-09\|title=Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/21572406\|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc\|volume=24\|issue=9\|pages=1169–1176\|doi=10.1038/modpathol.2011.86\|issn=1530-0285\|pmid=21572406}}</ref><ref name=":3">{{Cite journal\|last=D'Alfonso\|first=Timothy M.\|last2=Mosquera\|first2=Juan Miguel\|last3=MacDonald\|first3=Theresa Y.\|last4=Padilla\|first4=Jessica\|last5=Liu\|first5=Yi-Fang\|last6=Rubin\|first6=Mark A.\|last7=Shin\|first7=Sandra J.\|date=2014-11\|title=MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features\|url=https://pubmed.ncbi.nlm.nih.gov/25217885\|journal=Human Pathology\|volume=45\|issue=11\|pages=2270–2280\|doi=10.1016/j.humpath.2014.07.013\|issn=1532-8392\|pmid=25217885}}</ref><ref name=":4">{{Cite journal\|last=Mitani\|first=Yoshitsugu\|last2=Liu\|first2=Bin\|last3=Rao\|first3=Pulivarthi H.\|last4=Borra\|first4=Vishnupriya J.\|last5=Zafereo\|first5=Mark\|last6=Weber\|first6=Randal S.\|last7=Kies\|first7=Merrill\|last8=Lozano\|first8=Guillermina\|last9=Futreal\|first9=P. Andrew\|date=2016-02-01\|title=Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations\|url=https://pubmed.ncbi.nlm.nih.gov/26631609\|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research\|volume=22\|issue=3\|pages=725–733\|doi=10.1158/1078-0432.CCR-15-2867-T\|issn=1557-3265\|pmc=4807116\|pmid=26631609}}</ref> Fusions translocate super-enhancers in the partner gene to ''MYB''.<ref>{{Cite journal\|last=Drier\|first=Yotam\|last2=Cotton\|first2=Matthew J.\|last3=Williamson\|first3=Kaylyn E.\|last4=Gillespie\|first4=Shawn M.\|last5=Ryan\|first5=Russell J. H.\|last6=Kluk\|first6=Michael J.\|last7=Carey\|first7=Christopher D.\|last8=Rodig\|first8=Scott J.\|last9=Sholl\|first9=Lynette M.\|date=2016-03\|title=An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma\|url=https://pubmed.ncbi.nlm.nih.gov/26829750\|journal=Nature Genetics\|volume=48\|issue=3\|pages=265–272\|doi=10.1038/ng.3502\|issn=1546-1718\|pmc=4767593\|pmid=26829750}}</ref> Fusion transcripts lack ''MYB'' exon 15 including the 3' UTR, which contains target sites for microRNAs that negatively regulate ''MYB.''<ref name=":2" />
	\|t(6;9)(q23.3;p23)		\|t(6;9)(q23.3;p23)
	\|Common		\|Common
Line 127:		Line 123:
	==Characteristic Chromosomal or Other Global Mutational Patterns==		==Characteristic Chromosomal or Other Global Mutational Patterns==


	~~<br />~~
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 266:		Line 260:


	~~Put your text here~~


			<br />
	==Links==		==Links==
	https://www.pathologyoutlines.com/topic/breastmalignantadenoidcystic.html		https://www.pathologyoutlines.com/topic/breastmalignantadenoidcystic.html

Bailey.Glen at 13:38, 27 March 2025

2025-03-27T13:38:01Z

← Older revision		Revision as of 08:38, 27 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Adenoid cystic carcinoma}}		{{DISPLAYTITLE:Adenoid cystic carcinoma}}

	[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]		[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

Bailey.Glen: Repeat columns removed

2025-03-27T13:37:50Z

Repeat columns removed

Show changes

Bailey.Glen at 18:10, 24 March 2025

2025-03-24T18:10:16Z

Show changes

Kgeiersbach at 04:43, 9 January 2025

2025-01-09T04:43:20Z

← Older revision		Revision as of 23:43, 8 January 2025
Line 1:		Line 1:
	<br />		<br />
	==Primary Author(s)*==		==Primary Author(s)*==
	Jun Liao, PhD, Columbia University ~~and~~ Katherine Geiersbach, MD, Mayo Clinic - Rochester		Jun Liao, PhD, Columbia University Irving Medical Center, NY, USA

			Katherine Geiersbach, MD, Mayo Clinic - Rochester, MN, USA
	==WHO Classification of Disease==		==WHO Classification of Disease==
	<span style="color:#0070C0">(''Instructions: This table’s content from the WHO book will be <u>autocompleted</u>.'')</span>		<span style="color:#0070C0">(''Instructions: This table’s content from the WHO book will be <u>autocompleted</u>.'')</span>

Kgeiersbach at 01:58, 9 January 2025

2025-01-09T01:58:51Z

← Older revision		Revision as of 20:58, 8 January 2025
Line 219:		Line 219:
	\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.		\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
	==Epigenomic Alterations==		==Epigenomic Alterations==
	~~Put your text here~~		<br />
	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==
	~~Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Please include references throughout the table. Do not delete the table.)''~~</~~span~~>		<br />
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 235:		Line 235:
	\|}		\|}
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==
	Next generation sequencing for fusion detection and gene mutation profiling as applicable. Fluorescence in situ hybridization (FISH) for ''MYB'' rearrangement, typically with a "break-apart" probe design using differentially labeled 5' and 3' flanking probes to detect rearrangements of the ''MYB'' gene locus. Immunohistochemistry for MYB expression was more sensitive and specific than FISH in one study.<ref>{{Cite journal\|last=Poling\|first=Justin S.\|last2=Yonescu\|first2=Raluca\|last3=Subhawong\|first3=Andrea P.\|last4=Sharma\|first4=Rajni\|last5=Argani\|first5=Pedram\|last6=Ning\|first6=Yi\|last7=Cimino-Mathews\|first7=Ashley\|date=2017-07\|title=MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH\|url=https://pubmed.ncbi.nlm.nih.gov/28498281\|journal=The American Journal of Surgical Pathology\|volume=41\|issue=7\|pages=973–979\|doi=10.1097/PAS.0000000000000878\|issn=1532-0979\|pmid=28498281}}</ref>		Next generation sequencing for fusion detection and gene mutation profiling as applicable. Fluorescence in situ hybridization (FISH) for ''MYB'' rearrangement, typically with a "break-apart" probe design using differentially labeled 5' and 3' flanking probes to detect rearrangements of the ''MYB'' gene locus. Immunohistochemistry for MYB expression was more sensitive and specific than FISH in one study<ref>{{Cite journal\|last=Poling\|first=Justin S.\|last2=Yonescu\|first2=Raluca\|last3=Subhawong\|first3=Andrea P.\|last4=Sharma\|first4=Rajni\|last5=Argani\|first5=Pedram\|last6=Ning\|first6=Yi\|last7=Cimino-Mathews\|first7=Ashley\|date=2017-07\|title=MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH\|url=https://pubmed.ncbi.nlm.nih.gov/28498281\|journal=The American Journal of Surgical Pathology\|volume=41\|issue=7\|pages=973–979\|doi=10.1097/PAS.0000000000000878\|issn=1532-0979\|pmid=28498281}}</ref> but was demonstrated to be less specific with MYB staining also present in adenomyoepithelioma of the breast in another study.<ref>{{Cite journal\|last=Baraban\|first=Ezra\|last2=Zhang\|first2=Paul J.\|last3=Jaffer\|first3=Shabnam\|last4=Lubin\|first4=Daniel\|last5=Feldman\|first5=Michael\|last6=Bleiweiss\|first6=Ira J.\|last7=Nayak\|first7=Anupma\|date=2018-12\|title=MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma\|url=https://pubmed.ncbi.nlm.nih.gov/30003572\|journal=Histopathology\|volume=73\|issue=6\|pages=897–903\|doi=10.1111/his.13708\|issn=1365-2559\|pmid=30003572}}</ref>
	==Familial Forms==		==Familial Forms==
	~~Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>~~		None
	==Additional Information==		==Additional Information==
	Put your text here		Put your text here
	==Links==		==Links==
	Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www~~</nowiki>~~.~~" portion~~.~~'')<~~/~~span>~~		https://www.pathologyoutlines.com/topic/breastmalignantadenoidcystic.html
	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

Kgeiersbach at 01:05, 9 January 2025

2025-01-09T01:05:10Z

← Older revision		Revision as of 20:05, 8 January 2025
Line 160:		Line 160:
	\|		\|
	\|		\|
	\|Enriched in solid-type adenoid cystic carcinomas of the breast<ref name=":6" />		\|Enriched in solid-type adenoid cystic carcinomas of the breast<ref name=":6" /><ref name=":7" />
	\|-		\|-
	\|''KMT2C''		\|''KMT2C''
Line 168:		Line 168:
	\|		\|
	\|		\|
	\|		\|Enriched in solid-type adenoid cystic carcinomas of the breast<ref name=":7" />
	\|-		\|-
	\|''CREBBP''		\|''CREBBP''
Line 176:		Line 176:
	\|		\|
	\|		\|
	\|Enriched in solid-type adenoid cystic carcinomas of the breast<ref name=":6" />		\|Enriched in solid-type adenoid cystic carcinomas of the breast<ref name=":6" /><ref name=":7" />
	\|-		\|-
	\|''FBXW7''		\|''FBXW7''